Calendario›REGN›REGN9933

REGN9933

Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis

Ensayo de REGENERON PHARMACEUTICALS, INC. en End-Stage Kidney Disease (ESKD) (del registro, en inglés).

Fase

Fase 1

Estado

Aún sin reclutar

Participantes

36

previstos

Fin del objetivo primario

mar 2027

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en sep 2026.

Qué mide

Occurrence of Treatment-Emergent Adverse Events (TEAEs) (del registro, en inglés) (hasta unos 78 dias)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study will evaluate three Investigational Medicinal Products (IMPs) called REGN9933, REGN7508, and REGN9533. The study is focused on participants with End-Stage Kidney Disease (ESKD) treated with hemodialysis and standard anticoagulant treatment, such as heparin, to reduce the risk of blood clots as they can lead to serious health problems or be life-threatening. Because participants with ESKD who have hemodialysis have a higher risk of bleeding, the IMPs could be a meaningful new therapeutic option. The main aim of the study is to see what side effects may happen from taking REGN9933, REGN7508, or REGN9533. The study is looking at several other research questions, including: * How much IMP is in the blood at different times and * If the IMPs affect the ability of the blood to clot normally

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07759167), actualizada en ago 2026.